<SEC-DOCUMENT>0001193125-23-128718.txt : 20230501
<SEC-HEADER>0001193125-23-128718.hdr.sgml : 20230501
<ACCEPTANCE-DATETIME>20230501071451
ACCESSION NUMBER:		0001193125-23-128718
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230501
FILED AS OF DATE:		20230501
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		23869981

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d192840d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of May, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Chief Executive Officer; Resignation of Chief Executive Officer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2023, the Board of Directors (the &#147;Board&#148;) of Kazia Therapeutics Limited (the &#147;Company&#148;) announced that
Chief Executive Officer and Managing Director, Dr James Garner, has resigned from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;John Friend, Chief Medical
Officer of the Company will immediately assume the role of Chief Executive Officer, and will in due course join the Board as Managing Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Friend joined Kazia as Chief Medical Officer in November 2021. Since that time, he has been responsible for managing, and
instrumental in expanding Kazia&#146;s portfolio of clinical programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Friend is an accomplished physician executive with a more
than 25 year career history and extensive background in establishing and leading critical business units in small to <FONT STYLE="white-space:nowrap">mid-sized</FONT> biopharmaceutical companies. Prior to joining Kazia, he was Chief Medical Officer
at Cellectar Biosciences, Inc (NASDAQ: CLRB), a clinical-stage, oncology-focused biotech company based in Florham Park, NJ. Prior to his time at Cellectar, he held executive roles with responsibility for research&nbsp;&amp; development, regulatory
affairs, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Helsinn, Akros Pharma, Actavis, Alpharma, Hospira and Abbott. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Friend gained his medical degree at Rutgers University (UMDNJ-Robert Wood Johnson) and also holds a BA in chemistry from Southern
Methodist University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Garner will remain engaged through a transitional period to ensure a smooth handover of operational
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2023, the Company issued an ASX announcement titled, &#147;Kazia Announces Executive Leadership Changes.&#148;
A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates
by reference the information contained herein, including Exhibit 99.1, except for the quotes of Iain Ross and Dr.&nbsp;John Friend in Exhibit 99.1, into the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d192840dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated May 1, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 1&nbsp;May 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d192840dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g192840g0501123228320.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX ANNOUNCEMENT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> May 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dr John Friend appointed Chief Executive Officer, succeeding Dr James Garner </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 1</B><B><SUP STYLE="font-size:75%; vertical-align:top">st</SUP></B><B> May 2023</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an
oncology-focused drug development company, today announced that Chief Executive Officer and Managing Director, Dr James Garner, has resigned from the company. Dr John Friend, Chief Medical Officer of Kazia, will immediately assume the role of Chief
Executive Officer, and will in due course join the Board as Managing Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of Kazia,
Iain Ross, commented: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Dr James Garner joined Kazia in February 2016 and was responsible for the transformation of the legacy Novogen business into
the current organization. He drove the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of paxalisib and EVT801 and managed the deployment of a broad clinical program for both assets, in collaboration with leading cancer centres in the United
States and Europe. He leaves to pursue other opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the Board and on a personal basis, I want to thank James for his enormous
contribution to Kazia, and to wish him every success in his future endeavours. As Kazia now moves towards further clinical readouts and potential commercialisation of paxalisib, it is timely to reposition the company&#146;s executive team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr John Friend brings a wealth of drug development and business experience to Kazia and has made an excellent contribution during his time with the Company.
The Board is delighted that John has accepted the role of CEO as we believe he will be an excellent steward for the next phase of the Company&#146;s growth.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Dr John Friend </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Friend joined Kazia as Chief
Medical Officer in November 2021. Since that time, he has been responsible for managing, and instrumental in expanding Kazia&#146;s portfolio of clinical programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">He is an accomplished physician executive with a more than 25 year career history and extensive background in establishing and leading critical business units
in small to <FONT STYLE="white-space:nowrap">mid-sized</FONT> biopharmaceutical companies. Prior to joining Kazia, he was Chief Medical Officer at Cellectar Biosciences, Inc (NASDAQ: CLRB), a clinical-stage, oncology-focused biotech company based in
Florham Park, NJ. Prior to his time at Cellectar, he held executive roles with responsibility for research&nbsp;&amp; development, regulatory affairs, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies
including Helsinn Therapeutics, Akros Pharma, Actavis, Alpharma, Hospira and Abbott Laboratories. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Friend gained his medical degree at Rutgers University (UMDNJ-Robert Wood Johnson) and also holds a BA in
chemistry from Southern Methodist University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Friend commented: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I join Iain in adding my thanks to Dr James Garner for the many years of strong leadership he has delivered to Kazia. He leaves the company well
positioned with two excellent, unique clinical assets in paxalisib and EVT801, and a broad program of ongoing clinical trials, many of which are expected to produce data during CY2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We retain a highly accomplished, professional team which holds a deep understanding of our clinical assets and pipeline. I look forward to working closely
with Iain, together with the Board and team to drive the company forward as Kazia&#146;s next CEO.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Friend will continue to be based in the state
of New Jersey, USA on terms as outlined in Appendix A and Dr Garner will remain engaged through a transitional period to ensure a smooth handover of operational activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jane Lowe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+61 411 117 774 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;jane.lowe@irdepartment.com.au </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A
completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse
midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation
for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August
2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule
inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study
commenced recruitment in November 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by Iain Ross, Chairman&nbsp;&amp; Director. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib. Such statements are based on Kazia&#146;s expectations and projections about future events and future trends affecting its business and are subject to certain risks
and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to
regulatory approvals, risks related to Kazia&#146;s executive leadership changes, and the related to the impact of global economic conditions, including disruptions in the banking industry. These and other risks and uncertainties are described more
fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appendix A: Dr Friend&#146;s key terms of employment </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Base Salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">US$ 550,000 per annum (approximately AU$ 830,000 per annum)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benefits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr Friend receives contributions to a 401(k) retirement savings account, together with health, optical, and dental insurance, consistent with common practice for similar roles.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Short&nbsp;Term&nbsp;Incentives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 60% of base salary per annum, subject to attainment of key performance objectives</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Long Term Incentives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr Friend will be granted options over 3,000,000 shares of common stock in the company, with a strike price at market and a vesting schedule over 2 years.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Friend is employed &#145;at will&#146; and may resign his employment with the Company at any time.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In the event of termination by the company, change of control, or resignation for good
reason, Dr Friend is entitled to severance in the amount of six to twelve months&#146; compensation.</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g192840g0501123228320.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g192840g0501123228320.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X QD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#A:***[#C"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BE9'559D95894E2 ?IZTX12EE412%F&5&PY(]1ZT#&44I5@H8JP4]&(X
M/T-*(W8 K&Y#':"%)R?0>] AM%2?9YRA<6\Q0=6\LX&.O.*;L?9OV-LSC=M.
M,^F:!C:*7:VW=M.TG&['&?K3O*E!P8I!\N[[AZ>OT]Z &44[8^S?L;83C=M.
M,^F:-C[5;8^UCA3M.&/H/6@!M%.>.2(@2QO&2,@.I7/YT,CIC>C)D9&Y2,CU
MH ;12LK(VUT9&ZX8$&@*Q4L%8J.I X'UH$)14HMKAB0MM.2O! B8X^O%,\M\
MJ/+?+?=&T_-]/6@8VBE965BK*58=01@BDH$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=PISUXSCG)J+[5<^:TOVF;S&78S^8=Q7&,$YSC'&*.4.8V+K_DG-E_V%9_\
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MB7)13325];F1I=G->7&^&41F/#;SS@TFIR737;1W<@9XN!M&!19&\M[_ ,B
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M%*^BWD-N9I1#$3,\"Q/*!*[H0&55ZG!(%7_M^F7/BG[?<R,($17#-"2LLZJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2\LN%RF<G.0?O'J*9#?6EFM^L$:S+)(C0+-&2  2>1GJ,TE&/5C<ZFJ2[?\
M!*L&FWESYGE0_P"J;8^Y@NUO3D]:A%M,8UD"'8TGE*<]6]/UK3LM1@:VNUO9
M5$T\XE+26_F@\'/'8\U'8W-D+1+>ZEEC\FY\]&2/=O& ,=>#P*.6(<\TW=%>
M'2KV=IECAR86*R NHVD=>IJNT$JQ)*4.QV**?4CJ/U%7%O8VGU.612INHW"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
